The U.S. Facilities for Illness Management and Prevention (CDC) has chosen Retsef Levi, a member of its key vaccine panel, to guide its COVID-19 immunization workgroup, Reuters reported on August 25. “Levi had critiqued mRNA vaccines previously, saying they’ll trigger severe hurt and dying, particularly amongst youngsters, and referred to as for his or her instant withdrawal,” Reuters’ Mariam Sunny wrote.
Joseph Choi with The Hill wrote {that a} spokesperson for the Division of Well being and Human Companies (HHS) confirmed that Retsef Levi, professor of operations administration on the Massachusetts Institute of Know-how’s (MIT) Sloan Faculty of Administration, had been chosen to guide the working group.
“Levi was among the many eight new members of the CDC’s Advisory Committee on Immunization Practices (ACIP) chosen by HHS Secretary Robert F. Kennedy Jr. after he fired all standing members earlier this yr,” Choi reported.
“The CDC’s COVID-19 working group was created in 2020 to debate immunization suggestions because the pandemic advanced. The group is supposed to assist the work of the ACIP by means of the assessment of accessible information and scientific data,” Choi famous.
Tristan Manalac with BioSpace reported that the “COVID-19 immunization workgroup will operate as a subgroup of the CDC’s Advisory Committee on Immunization Practices (ACIP), as per the company’s doc. The subcommittee will primarily serve ‘to assessment related revealed and unpublished information, and scientific and scientific data’ and provide you with ‘choices’ that it’s going to then current to ACIP throughout public conferences to assist the advisory panel craft vaccination suggestions.”
“Levi’s vaccine skepticism was on full show throughout the latest ACIP assembly in June, when the panel was purported to—however finally didn’t—vote on COVID-19 immunization tips. Even when confronted with proof displaying that vaccines containing thimerosal are secure, Levi declined to agree,” Manalac wrote.
Moreover, Manalac reported, “Levi was additionally one among two panelists who voted towards recommending Merck’s respiratory syncytial virus antibody Enflonsia to be used in infants—a advice ACIP finally endorsed.”
